Which has stronger valuation & earnings, DRUG or IRON?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is DRUG or IRON more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Disc Medicine N/A -37.17% -33.65%

Does the media refer more to DRUG or IRON?

In the previous week, Disc Medicine had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Disc Medicine and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Disc Medicine's score of 0.68 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or DRUG?

In the previous week, Beam Therapeutics had 12 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 16 mentions for Beam Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Beam Therapeutics' score of -0.42 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, DRUG or IMNM?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Immunome N/A N/A -$212.39M -$2.53 N/A

Is DRUG or IMNM more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Immunome N/A -50.56% -46.93%

Does the media favor DRUG or IMNM?

In the previous week, Immunome had 30 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 34 mentions for Immunome and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Immunome's score of 0.33 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 13 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, DRUG or KOD?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Kodiak Sciences N/A N/A -$229.97M -$4.19 N/A

Is DRUG or KOD more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Kodiak Sciences N/A -247.63% -82.91%

Does the media refer more to DRUG or KOD?

In the previous week, Kodiak Sciences had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 13 mentions for Kodiak Sciences and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Kodiak Sciences' score of 0.22 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DRUG or NRIX?

In the previous week, Nurix Therapeutics had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 14 mentions for Nurix Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Nurix Therapeutics' score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Bright Minds Biosciences (DRUG) Competitors

$76.44 -1.56 (-2.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.25 -0.19 (-0.25%)

As of 08/14/2026 07:34 PM Eastern

Compare

DRUG vs. IRON, BEAM, IMNM, KOD, and NRIX

Should you buy Bright Minds Biosciences stock or one of its competitors? Bright Minds Biosciences's main competitors and comparable companies include Disc Medicine (IRON), Beam Therapeutics (BEAM), Immunome (IMNM), Kodiak Sciences (KOD), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bright Minds Biosciences compare to Disc Medicine?

Bright Minds Biosciences (NASDAQ:DRUG) and Disc Medicine (NASDAQ:IRON) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Disc Medicine had 8 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 12 mentions for Disc Medicine and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Disc Medicine's score of 0.68 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences has a beta of -5.27, indicating that its stock price is 627% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bright Minds Biosciences' return on equity of -20.58% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Disc Medicine	N/A	-37.17%	-33.65%

Bright Minds Biosciences presently has a consensus target price of $143.83, indicating a potential upside of 88.17%. Disc Medicine has a consensus target price of $106.00, indicating a potential upside of 34.45%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Bright Minds Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Bright Minds Biosciences beats Disc Medicine on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

In the previous week, Beam Therapeutics had 12 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 16 mentions for Beam Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Beam Therapeutics' score of -0.42 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Bright Minds Biosciences' return on equity of -20.58% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Bright Minds Biosciences has lower revenue, but higher earnings than Beam Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$156.04M	17.71	-$79.99M	-$0.86	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beam Therapeutics currently has a consensus target price of $49.00, indicating a potential upside of 83.18%. Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 88.17%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Bright Minds Biosciences is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, indicating that its stock price is 627% less volatile than the broader market.

Summary

Bright Minds Biosciences beats Beam Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Immunome?

Bright Minds Biosciences (NASDAQ:DRUG) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Bright Minds Biosciences' return on equity of -20.58% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Immunome	N/A	-50.56%	-46.93%

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 88.17%. Immunome has a consensus target price of $34.64, suggesting a potential upside of 27.34%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Bright Minds Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Immunome	N/A	N/A	-$212.39M	-$2.53	N/A

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bright Minds Biosciences has a beta of -5.27, suggesting that its stock price is 627% less volatile than the broader market. Comparatively, Immunome has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

In the previous week, Immunome had 30 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 34 mentions for Immunome and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Immunome's score of 0.33 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	13 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bright Minds Biosciences beats Immunome on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Kodiak Sciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Bright Minds Biosciences' return on equity of -20.58% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Kodiak Sciences	N/A	-247.63%	-82.91%

Bright Minds Biosciences presently has a consensus price target of $143.83, suggesting a potential upside of 88.17%. Kodiak Sciences has a consensus price target of $48.14, suggesting a potential upside of 16.43%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Bright Minds Biosciences is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Bright Minds Biosciences has a beta of -5.27, suggesting that its share price is 627% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

In the previous week, Kodiak Sciences had 9 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 13 mentions for Kodiak Sciences and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Kodiak Sciences' score of 0.22 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Summary

Bright Minds Biosciences beats Kodiak Sciences on 8 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Bright Minds Biosciences has higher earnings, but lower revenue than Nurix Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Nurix Therapeutics	$36.77M	76.36	-$264.46M	-$3.45	N/A

40.5% of Bright Minds Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences has a beta of -5.27, suggesting that its share price is 627% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Bright Minds Biosciences' return on equity of -20.58% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Bright Minds Biosciences currently has a consensus target price of $143.83, indicating a potential upside of 88.17%. Nurix Therapeutics has a consensus target price of $34.21, indicating a potential upside of 26.49%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Nurix Therapeutics had 10 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 14 mentions for Nurix Therapeutics and 4 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.45 beat Nurix Therapeutics' score of 0.83 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bright Minds Biosciences beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$759.11M	$3.72B	$7.02B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-31.33	10.72	270.72	25.33
Price / Sales	N/A	1,233.84	574.35	73.89
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	9.18	16.78	12.92	6.25
Net Income	-$8.74M	-$13.32M	$3.45B	$347.82M
7 Day Performance	-3.64%	1.75%	1.15%	1.08%
1 Month Performance	0.68%	1.13%	1.37%	0.82%
1 Year Performance	82.78%	54.35%	62.52%	20.99%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	3.2191 of 5 stars	$76.44 -2.0%	$143.83 +88.2%	+79.7%	$759.11M	N/A	N/A	N/A	Positive News Earnings Report
IRON Disc Medicine	2.6399 of 5 stars	$77.80 +2.0%	$104.44 +34.2%	+29.8%	$2.97B	N/A	N/A	30
BEAM Beam Therapeutics	1.7481 of 5 stars	$28.35 +9.4%	$46.85 +65.2%	+51.7%	$2.92B	$139.74M	N/A	510	Analyst Revision Gap Up
IMNM Immunome	2.8258 of 5 stars	$25.06 +8.9%	$33.17 +32.3%	+173.6%	$2.84B	$6.94M	N/A	40	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
KOD Kodiak Sciences	1.9951 of 5 stars	$42.89 +7.7%	$48.14 +12.2%	+311.9%	$2.68B	N/A	N/A	90	News Coverage Earnings Report Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. IRON, BEAM, IMNM, KOD, and NRIX

How does Bright Minds Biosciences compare to Disc Medicine?

Summary

How does Bright Minds Biosciences compare to Beam Therapeutics?

Summary

How does Bright Minds Biosciences compare to Immunome?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Summary

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. IRON, BEAM, IMNM, KOD, and NRIX

How does Bright Minds Biosciences compare to Disc Medicine?

Does the media refer more to DRUG or IRON?

Which has more volatility & risk, DRUG or IRON?

Which has stronger valuation & earnings, DRUG or IRON?

Do insiders and institutionals have more ownership in DRUG or IRON?

Is DRUG or IRON more profitable?

Do analysts rate DRUG or IRON?

Summary

How does Bright Minds Biosciences compare to Beam Therapeutics?

Does the media prefer BEAM or DRUG?

Is BEAM or DRUG more profitable?

Which has preferable earnings and valuation, BEAM or DRUG?

Do institutionals and insiders have more ownership in BEAM or DRUG?

Do analysts prefer BEAM or DRUG?

Which has more risk and volatility, BEAM or DRUG?

Summary

How does Bright Minds Biosciences compare to Immunome?

Is DRUG or IMNM more profitable?

Do analysts rate DRUG or IMNM?

Which has preferable earnings and valuation, DRUG or IMNM?

Do insiders & institutionals have more ownership in DRUG or IMNM?

Which has more volatility and risk, DRUG or IMNM?

Does the media favor DRUG or IMNM?

Summary

How does Bright Minds Biosciences compare to Kodiak Sciences?

Is DRUG or KOD more profitable?

Do analysts rate DRUG or KOD?

Which has more volatility & risk, DRUG or KOD?

Does the media refer more to DRUG or KOD?

Do institutionals and insiders have more ownership in DRUG or KOD?

Which has stronger valuation and earnings, DRUG or KOD?

Summary

How does Bright Minds Biosciences compare to Nurix Therapeutics?

Which has preferable valuation & earnings, DRUG or NRIX?

Do insiders and institutionals have more ownership in DRUG or NRIX?

Which has more risk and volatility, DRUG or NRIX?

Is DRUG or NRIX more profitable?

Do analysts rate DRUG or NRIX?

Does the media prefer DRUG or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools